Free Trial
NASDAQ:AXDX

Accelerate Diagnostics Q4 2024 Earnings Report

Accelerate Diagnostics logo
$0.04 +0.04 (+∞)
As of 05/14/2025
This is a fair market value price provided by Polygon.io. Learn more.

Accelerate Diagnostics EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.13
One Year Ago EPS
N/A

Accelerate Diagnostics Revenue Results

Actual Revenue
$2.82 million
Expected Revenue
$3.00 million
Beat/Miss
Missed by -$184.00 thousand
YoY Revenue Growth
N/A

Accelerate Diagnostics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 21, 2025
Conference Call Time
8:00AM ET

Accelerate Diagnostics Earnings Headlines

While others chase AI stocks, smart traders do this
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
See More Accelerate Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Accelerate Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Accelerate Diagnostics and other key companies, straight to your email.

About Accelerate Diagnostics

Accelerate Diagnostics (NASDAQ:AXDX), an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

View Accelerate Diagnostics Profile

More Earnings Resources from MarketBeat